A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (greater than or equal to 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Bendamustine (Primary) ; Ibrutinib (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Dec 2018 Results assessing efficacy of Ibrutinib was superior in comparison with treatment with bendamustine plus rituximab in untreated patients with Chronic lymphocytic leukaemia, published in the New England Journal of Medicine.
- 31 Aug 2018 Biomarkers information updated
- 03 May 2018 Planned primary completion date changed from 16 May 2018 to 28 Feb 2019.